Kilitch Drugs (India) Limited (NSE:KILITCH)
India · Delayed Price · Currency is INR 185.86
+3.17 (1.74%)
Jun 19, 2026, 3:30 PM IST
Kilitch Drugs (India) Revenue
In the fiscal year ending March 31, 2026, Kilitch Drugs (India) had annual revenue of 2.35B INR with 18.74% growth. Kilitch Drugs (India) had revenue of 896.03M in the quarter ending March 31, 2026, with 46.35% growth.
Revenue
2.35B
Revenue Growth
+18.74%
P/S Ratio
2.75
Revenue / Employee
12.59M
Employees
187
Market Cap
6.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.35B | 371.56M | 18.74% |
| Mar 31, 2025 | 1.98B | 439.46M | 28.47% |
| Mar 31, 2024 | 1.54B | 147.74M | 10.58% |
| Mar 31, 2023 | 1.40B | 253.65M | 22.20% |
| Mar 31, 2022 | 1.14B | 457.11M | 66.71% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.45B |
| Windlas Biotech | 9.04B |
| Ind-Swift Laboratories | 6.41B |
| Sigachi Industries | 4.86B |
| Beta Drugs | 3.85B |
| Jagsonpal Pharmaceuticals | 2.87B |
| Sakar Healthcare | 2.52B |
| Valiant Laboratories | 2.37B |
Kilitch Drugs (India) News
- 1 year ago - Kilitch Drugs India shares surge over 2% as company invests $200,000 in Kilitch Estro Biotech - Business Upturn